Spruce Biosciences Inc. (SPRB)
0.37
-0.00 (-0.38%)
At close: Jan 15, 2025, 3:59 PM
0.36
-1.49%
After-hours Jan 15, 2025, 04:27 PM EST
undefined% (undefined)
| Bid | 0.37 |
| Market Cap | 15.22M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.95 |
| PE Ratio (ttm) | -0.39 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.38 |
| Volume | 200,673 |
| Avg. Volume (20D) | 627,183 |
| Open | 0.38 |
| Previous Close | 0.37 |
| Day's Range | 0.36 - 0.39 |
| 52-Week Range | 0.34 - 5.95 |
| Beta | undefined |
About SPRB
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adu...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 9, 2020
Employees 29
Stock Exchange NASDAQ
Ticker Symbol SPRB
Analyst Forecast
According to 7 analyst ratings, the average rating for SPRB stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 442.74% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
Next Earnings Release
Spruce Biosciences Inc. is scheduled to release its earnings on Mar 12, 2025,
during market hours.
Analysts project revenue of $1.12M, reflecting a -61.21% YoY shrinking and earnings per share of -0.25, making a 8.70% increase YoY.
Analysts project revenue of $1.12M, reflecting a -61.21% YoY shrinking and earnings per share of -0.25, making a 8.70% increase YoY.
1 month ago ·
Source
-20.02%
Spruce Biosciences shares are trading lower after ...
Unlock content with
Pro Subscription
10 months ago ·
Source
-84.38%
Spruce Biosciences shares are trading lower after the company reported FY23 financial results. Also, the company announced that the CAHmedlia-203 study of Tildacerfont in adult classic congenital adrenal hyperplasia with severe hyperandrogenemia did not meet its primary efficacy endpoint.
